Volume | 791,566 |
|
|||||
News | - | ||||||
Day High | 6.4094 | Low High |
|||||
Day Low | 6.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Verve Therapeutics Inc | VERV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.26 | 6.02 | 6.4094 | 6.16 | 6.22 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,849 | 791,566 | $ 6.20 | $ 4,911,517 | - | 6.02 - 21.4199 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:40:09 | 1 | $ 6.18 | USD |
Verve Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
515.09M | 83.62M | - | 11.76M | -200.07M | -2.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Verve Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.59 | 7.41 | 6.02 | 6.62 | 1,039,145 | -0.26 | -3.95% |
1 Month | 13.24 | 13.24 | 6.02 | 8.00 | 1,693,603 | -6.91 | -52.19% |
3 Months | 10.89 | 19.34 | 6.02 | 11.52 | 1,327,503 | -4.56 | -41.87% |
6 Months | 9.41 | 20.12 | 6.02 | 12.03 | 1,511,131 | -3.08 | -32.73% |
1 Year | 15.72 | 21.4199 | 6.02 | 13.10 | 1,088,670 | -9.39 | -59.73% |
3 Years | 30.00 | 78.00 | 6.02 | 21.89 | 865,162 | -23.67 | -78.90% |
5 Years | 30.00 | 78.00 | 6.02 | 21.89 | 865,162 | -23.67 | -78.90% |
Verve Therapeutics Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. |